StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.24−0.16 (-6.67%)

Close on Nov 16, 2026Market cap $5.06MP/E –Yield –

Biodexa Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was £3.96M, down 27.1% from the year before. Over ten years it grew -7.6% a year on average. The highest annual figure on record is £9.36M in fiscal 2018.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025£3.96M-27.1%
FY2024Dec 31, 2024£5.44M+33.7%
FY2023Dec 31, 2023£4.07M-20.4%
FY2022Dec 31, 2022£5.11M+9.8%
FY2021Dec 31, 2021£4.65M-23.3%
FY2020Dec 31, 2020£6.07M-22.6%
FY2019Dec 31, 2019£7.84M-16.2%
FY2018Dec 31, 2018£9.36M+12.4%
FY2017Dec 31, 2017£8.33M+7.7%
FY2016Dec 31, 2016£7.73M-11.3%
FY2015Dec 31, 2015£8.71M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?